Close Menu

NYGC

The grant is part of a CZI effort to fund research projects supporting the Human Cell Atlas, which is building a reference atlas of all human cell types.

The five-year gift will support the building and maintenance of the NYGC's genomics infrastructure to work with its institutional founding members.

With DNA methylation data for more than 1,800 chronic lymphocytic leukemia B cells, researchers tracked CLL epimutation rates and saw lineages with distinct treatment responses.

Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.

The method builds on a previous technique the group developed to measure transcriptomes and surface proteins from single cells.

The researchers uncovered disease-linked genes that are expressed in certain cells and disease stages and discovered various gene expression modules.

The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.

The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.

While the New York Genome Center says whole-genome cancer sequencing is the future, companies already offering such tests are struggling to get paid.

The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.